Stockscreener 앱 받기
1.78
3.26%
-0.06
시간 외 거래:
1.77
-0.01
-0.56%
전일 마감가:
$1.84
열려 있는:
$1.85
하루 거래량:
40,955
Relative Volume:
0.02
시가총액:
$7.41M
수익:
-
순이익/손실:
$-15.47M
주가수익비율:
-3.56
EPS:
-0.5
순현금흐름:
$-13.51M
1주 성능:
-6.32%
1개월 성능:
-17.97%
6개월 성능:
-69.33%
1년 성능:
-87.56%
1일 변동 폭
$1.77
$1.85
1주일 범위
$1.72
$1.9212
52주 변동 폭
$1.71
$18.39
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
NLSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
1.78 | 7.41M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nls Pharmaceutics Ltd 주식(NLSP)의 최신 뉴스
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - ACCESS Newswire
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire
NLS Pharmaceutics reports progress in narcolepsy treatment - Investing.com
Can NLS Pharmaceutics' Orexin Agonist Treat More Than Just Sleep Disorders? New Data Says Yes - StockTitan
NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - PR Newswire
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder - ACCESS Newswire
NLS Pharmaceutics And Kadimastem Unveil Multi-Target Diabetes Approach - Nasdaq
Is NLSP’s price to cash per share ratio a concern for investors? - US Post News
NLS Pharmaceutics Ltd’s Shares Reel: -37.16% Quarterly Revenue Decline Amid 6.35M Market Cap - The InvestChronicle
NLS Pharmaceutics Ltd (NLSP) Shares Rise Despite Market Challenges - The News Heater
Stock market today: Patriot National Bancorp +46.21%, NLS Pharmaceutics +37.43% among top gainers in early trading - Business Upturn
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - GuruFocus.com
NLS Pharmaceutics (NLSP) Shares Surge As Market Reacts To Potential Merger - Stocks Telegraph
NLS Pharmaceutics and Kadimastem Announce Merger to Innovate Diabetes Treatment - TipRanks
Are NLS Pharmaceutics Ltd’shares a good deal? - US Post News
Navigating NLSP Stock: NLS Pharmaceutics Ltd Journey - The InvestChronicle
NLS Pharmaceutics Ltd (NASDAQ: NLSP) Defies Bearish Expectations and Displays Strong Future Potential - Marketing Sentinel
NLS and Kadimastem move forward with merger plans - MSN
Israeli startup Kadimastem to merge With NLS Pharmaceutics - MSN
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference - ACCESS Newswire
NLS and Kadimastem move forward with merger plans By Investing.com - Investing.com Canada
NLS Gains on Deal with Kardimastem - Baystreet.ca
Kadimastem Shareholders Greenlight Merger with NLS - Sleep Review
NLS Pharmaceutics Amends Merger Agreement with Kadimastem - TipRanks
Stock market news: Reborn Coffee +65.76%, NLS Pharmaceutics +30.81% among top gainers during mid day trading - Business Upturn
NLS Pharmaceutics Says Kadimastem Shareholders Approve Merger With NLS; Shares Rise - Marketscreener.com
NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice - ACCESS Newswire
Kadimastem Shareholders Approve Merger with NLS Pharmaceutics - TipRanks
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics -January 31, 2025 at 07:31 am EST - Marketscreener.com
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics - Nasdaq
NLS Pharmaceutics and Kadimastem Move Forward with Merger to Create Nasdaq-Traded Biotechnology Company - HPBL
NLS Abstracts Showcase Narcolepsy and Diabetes-Related Sleep Research - Sleep Review
NLS Pharmaceutics and Kadimastem Merger & Financing Update – Market - HPBL
NLS Pharmaceutics Submits Research Abstracts to ASCP 2025 - TipRanks
Revolutionary Fentanyl Addiction Treatment Among 3 Major Breakthroughs from NLS Pharma - StockTitan
NLS Pharmaceutics Ltd (NLSP) Has A Bright Growth Prospects For 2025 - Marketing Sentinel
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire
NLS Pharmaceutics Launches Preclinical Program for Fentanyl Dependence Treatment - TipRanks
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Marketscreener.com
Game-Changing Drug Could End Fentanyl Epidemic: NLS Pharma's Bold Move - StockTitan
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - ACCESS Newswire
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions - ACCESS Newswire
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - ACCESS Newswire
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance - ACCESS Newswire
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing - ACCESS Newswire
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform - ACCESS Newswire
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - ACCESS Newswire
NLS Pharmaceutics Announces Company Update on Strategic Partnerships - ACCESS Newswire
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - ACCESS Newswire
Nls Pharmaceutics Ltd (NLSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.45%
1.23%
자본화:
|
볼륨(24시간):